1. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. (February 2023) Authors: Liu, Zhigang; Le, Kaixing; Zhou, Xin; Alexander, James L; Lin, Simeng; Bewshea, Claire; Chanchlani, Neil; Nice, Rachel; McDonald, Timothy J; Lamb, Christopher A; Sebastian, Shaji; Kok, Klaartje; Lees, Charlie W; Hart, Ailsa L; Pollok, Richard C; Boyton, Rosemary J; Altmann, Daniel M; Pollock, Kat... Journal: Lancet gastroenterology and hepatology Issue: Volume 8:Number 2(2023) Page Start: 145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting. (31st December 2022) Authors: Kato, Shumei; Li, Bing; Adashek, Jacob J.; Cha, Seong Won; Bianchi-Frias, Daniella; Qian, Dajun; Kim, Lisa; so, Tiffany W; Mitchell, Marcus; Kamei, Naoki; Hoiness, Robert; Hoo, Jayne; Gray, Phillip N.; Iyama, Teruaki; Kashiwagi, Masahide; Lu, Hsiao-Mei; Kurzrock, Razelle Journal: Oncoimmunology Issue: Volume 11:Number 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗